Botox Rival Can Stay On Market Following Allergan Deal

Law360 (February 19, 2021, 5:36 PM EST) -- Evolus and Allergan announced a deal Friday that resolves trade secret theft allegations against Evolus, allowing Evolus' low-cost version of Allergan's Botox to stay on the market in the U.S. in exchange for milestone royalty payments.

The announcement of the settlement came roughly two months after the U.S. International Trade Commission found that Evolus, which licenses the Jeuveau neurotoxin injection from South Korea-based Daewoong Pharmaceutical Co. Ltd., should be barred from importing Jeuveau for 21 months for misappropriating manufacturing trade secrets.

AbbVie and Allergan's Korean partner Medytox said as part of the settlement Evolus will make milestone and royalty payments and...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!